AMSTERDAM, The Netherlands -- Primagen Holding B.V., a provider of molecular diagnostics tests for infectious diseases, AIDS and cancer, announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for the use of mitochondrial nucleic acid as a tool to measure toxicity and efficacy of pharmaceutical compounds. Mitochondrial Toxicity assessment is an integral part of the companys plans to introduce a broad array of Mitox applications that can be used to manage and treat disease.
The notice of allowance indicates that the company has fulfilled all requirements for the issuance of a new patent entitled, Method of determining therapeutic activity and/or possible side-effects of a medicament, expected to be issued in the next two to three months. The companys proprietary mitochondrial nucleic acid marker technology provides researchers and clinicians the ability to measure mitochondrial nucleic acid levels with a simple real time molecular diagnostics test.
The issuance of the mitochondrial DNA patent is a key milestone for the company and the business development strategy for our North American operations, said Steve Owings, president of Primagen Inc. Combined with previous license agreements in the field of mitochondrial testing, this patent solidifies our leadership in this expanding field with a focus on antiretroviral HIV-1 treatment, applications for Hepatis C, cancer and statins which are used to manage high cholesterol conditions.
This is the first patent allowance for our family of Mitox applications that were filed world-wide, and we strongly believe that allowances in other key markets will follow soon, said Bob van Gemen, chief executive officer of Primagen Holding B.V. Our Mitox products are currently used in the United States and Europe, with additional market expansion planned for 2005 in the Far East, Australia and Latin America.
Source: Primagen Holding B.V.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.